# Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

> **NCT05340413** · PHASE2 · COMPLETED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 65 (actual)

## Conditions studied

- HER2-negative Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05340413
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-25
- **Primary completion:** 2025-02-03
- **Final completion:** 2025-02-03
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05340413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05340413, "Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05340413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*